Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly
Tóm tắt
The aim of this study was to assess the effects of replacement with recombinant human growth hormone (rhGH) in patients with GH deficiency (GHD) after treatment of acromegaly. Intervention study. Sixteen patients (8 men, age 56 years), treated for acromegaly by surgery and radiotherapy, with an insufficient GH response to insulin-induced hypoglycaemia, were treated with 1 year of rhGH replacement. Study parameters were assessed at baseline and after 1 year of rhGH replacement. Study parameters were cardiac function, body composition, bone mineral density (BMD), fasting lipids, glucose, bone turnover markers, and Quality of Life (QoL). During rhGH replacement IGF-I concentrations increased from −0.4 ± 0.7 to 1.0 ± 1.5 SD (P = 0.001), with a mean daily dose of 0.2 ± 0.1 mg in men and 0.3 ± 0.2 mg in women. Nonetheless, rhGH replacement did not alter cardiac function, lipid and glucose concentrations, body composition or QoL. Bone turnover markers (PINP and β crosslaps) levels increased (P = 0.005 and P = 0.021, respectively), paralleled by a small, but significant decrease in BMD of the hip. The beneficial effects of rhGH replacement in patients with GHD during cure from acromegaly are limited in this study.
Tài liệu tham khảo
de Boer H, Blok GJ, Van der Veen EA (1995) Clinical aspects of growth hormone deficiency in adults. Endocr Rev 16:63–86. doi:10.1210/er.16.1.63
Maison P, Demolis P, Young J, Schaison G, Giudicelli JF, Chanson P (2000) Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol (Oxf) 53:445–451. doi:10.1046/j.1365-2265.2000.01127.x
Chrisoulidou A, Beshyah SA, Rutherford O, Spinks TJ, Mayet J, Kyd P, Anyaoku V, Haida A, Ariff B, Murphy M, Thomas E, Robinson S, Foale R, Johnston DG (2000) Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 85:3762–3769. doi:10.1210/jc.85.10.3762
Gotherstrom G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B, Johannsson G (2001) A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 86:4657–4665. doi:10.1210/jc.86.10.4657
Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML (1989) Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med 70:145–160
Biermasz NR, van Dulken H, Roelfsema F (2000) Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 85:2476–2482. doi:10.1210/jc.85.7.2476
Feldt-Rasmussen U, Abs R, Bengtsson BA, Bennmarker H, Bramnert M, Hernberg-Stahl E, Monson JP, Westberg B, Wilton P, Wuster C (2002) Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing’s disease. Eur J Endocrinol 146:67–74. doi:10.1530/eje.0.1460067
Norrman LL, Johannsson G, Sunnerhagen KS, Svensson J (2008) Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly. J Clin Endocrinol Metab 63:2531–2538
van der Klaauw AA, Pereira AM, van Thiel SW, Smit JW, Corssmit EP, Biermasz NR, Frolich M, Iranmanesh A, Veldhuis JD, Roelfsema F, Romijn JA (2006) GH deficiency in patients irradiated for acromegaly: significance of GH stimulatory tests in relation to the 24 h GH secretion. Eur J Endocrinol 154:851–858. doi:10.1530/eje.1.02163
Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency (1998). J Clin Endocrinol Metab 83:379–381
Roelfsema F, van den Berg G, van Dulken H, Veldhuis JD, Pincus SM (1998) Pituitary apoplexy in acromegaly, a long-term follow-up study in two patients. J Endocrinol Invest 21:298–303
Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 2:358–367
Perry GJ, Helmcke F, Nanda NC, Byard C, Soto B (1987) Evaluation of aortic insufficiency by Doppler color flow mapping. J Am Coll Cardiol 9:952–959
Thomas JD (1997) How leaky is that mitral valve? Simplified Doppler methods to measure regurgitant orifice area. Circulation 95:548–550
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450–458. doi:10.1016/0002-9149(86)90771-X
Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370. doi:10.1111/j.1600-0447.1983.tb09716.x
Smets EM, Garssen B, Bonke B, De Haes JC (1995) The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39:315–325. doi:10.1016/0022-3999(94)00125-O
Hunt SM, McEwen J (1980) The development of a subjective health indicator. Sociol Health Illn 2:231–246. doi:10.1111/1467-9566.ep11340686
Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J, Papp E (1980) A quantitative approach to perceived health status: a validation study. J Epidemiol Community Health 34:281–286. doi:10.1136/jech.34.4.281
McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L, Wiren L (1999) The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 8:373–383. doi:10.1023/A:1008987922774
Cole TJ (1990) The LMS method for constructing normalized growth standards. Eur J Clin Nutr 44:45–60
Rikken B, van Doorn J, Ringeling A, Van den Brande JL, Massa G, Wit JM (1998) Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Horm Res 50:166–176. doi:10.1159/000023268
Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J (2007) Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol 156:55–64. doi:10.1530/eje.1.02317
Maison P, Chanson P (2003) Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108:2648–2652. doi:10.1161/01.CIR.0000100720.01867.1D
Deijen JB, Arwert LI, Witlox J, Drent ML (2005) Differential effect sizes of growth hormone replacement on quality of life, well-being and health status in growth hormone deficient patients: a meta-analysis. Health Qual Life Outcomes 3:63. doi:10.1186/1477-7525-3-63
Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 89:2192–2199. doi:10.1210/jc.2003-030840
Davidson P, Milne R, Chase D, Cooper C (2004) Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 60:92–98. doi:10.1111/j.1365-2265.2004.01935.x
Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J (2007) A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 92:1442–1445. doi:10.1210/jc.2006-1487
van der Klaauw AA, Romijn JA, Biermasz NR, Smit JW, van Doorn J, Dekkers OM, Roelfsema F, Pereira AM (2006) Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. Eur J Endocrinol 155:701–708. doi:10.1530/eje.1.02283
van der Klaauw AA, Biermasz NR, Feskens EJ, Bos MB, Smit JW, Roelfsema F, Corssmit EP, Pijl H, Romijn JA, Pereira AM (2007) The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol 156:455–462. doi:10.1530/EJE-06-0699
Monson JP, Jonsson P, Koltowska-Haggstrom M, Kourides I (2007) Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. Clin Endocrinol (Oxf) 67:623–628
Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F (2001) Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. J Clin Endocrinol Metab 86:3079–3085. doi:10.1210/jc.86.7.3079
Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152. doi:10.1210/er.2002-0022
Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F (2005) Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. Eur J Endocrinol 152:53–60. doi:10.1530/eje.1.01820
Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Morbidity after long-term remission for acromegaly; persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90:2731–2739
van der Klaauw AA, Biermasz N, Hoftijzer HC, Pereira AM, Romijn JA (2008) Previous radiotherapy negatively influences quality of life during four years of follow-up in patients cured from acromegaly. Clin Endocrinol (Oxf) 69(1):123–128